UROV - Urovant Sciences Is A Hidden Gem With A Blockbuster Drug Likely To Be Approved This Year And 'Short Squeeze' Potential. PT: $43
This article was highlighted for PRO+ subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here.
Urovant Sciences (UROV) is a hidden gem—a significantly undervalued company that has been significantly de-risked over the past twelve months:
- Clinical data risk: The company released pristine Phase 3 data in March 2019, showing that its key asset (vibegron) has a clear value proposition over the existing branded leader in the market (mirabegron) for the treatment of overactive bladder.
- Safety risk: One concern heading both into